The Norditropin® Patient Access Program (PAP) reflects our commitment to social responsibility and our belief that a lack of financial resources should not stand in the way of necessary medical care. Through the Norditropin® PAP, those who qualify may receive free medicine. Eligibility is based on financial resources, cost of living, size of household, and out-of-pocket medical costs.
The Norditropin® PAP is administered by NordiCare®, a comprehensive support program serving the needs of patients with growth hormone-related disorders and those who care for them For more information on NordiCare®, please click here.
Upon approval, NordiCare® will ship a free 30-day supply of Norditropin® directly to the patient’s home. Patients are eligible to remain in the program and receive monthly shipments as long as their financial and insurance situation does not enable them to afford Norditropin®. Every 6 months, a NordiCare® Case Manager will contact the patient to evaluate whether assistance is still required.
Please contact your healthcare professional if you believe that you or someone you know should be considered for the Norditropin® PAP.
Get started with NordiCare® today. Call 1-888-NOVO-444.
If you are a healthcare professional and would like to learn how to put NordiCare® to work for your patients, click here.
NORDITROPIN® Indications and Usage: Norditropin® (somatropin [rDNA origin] injection) is used to treat children with growth failure caused by very low or no production of growth hormone. It is also used to treat children who have short stature associated with Noonan syndrome or Turner syndrome and to treat adults who do not make enough growth hormone.
Important Safety Information:
Remember, your doctor is the main source of information about you and your health. Please consult your doctor if you have any questions about your health or your medication.
Do not use Norditropin®if you have any of the following conditions: an allergy to phenol or any other ingredients in the medicine; active cancer or other forms of tumor; acute critical illness due to certain types of heart or abdomen surgery, trauma, or acute respiratory failure.
Children should not use somatropin if they have any of the following conditions: closed epiphyses (closed bone growth plates), Prader-Willi syndrome with severe obesity, or Prader-Willi syndrome with significant respiratory impairment.
Be sure to tell your doctor if you have diabetes mellitus; have had cancer or other forms of tumor; are pregnant, planning to be pregnant or are breastfeeding; or if you have had a kidney transplant.
Be sure to tell your doctor about all medications you are taking especially if they are: a glucocorticoid medication such as hydrocortisone or cortisone acetate, thyroid hormone, insulin and/or oral diabetes medicines, drugs metabolized by the liver (for example, corticosteroids, sex steroids, anticonvulsants, cyclosporine), or oral estrogen replacement.
Adult height can be influenced if you are on Norditropin® for growth failure and at the same time using glucocorticoids or thyroid hormone.
If you are treated with insulin and/or oral diabetes medicines, the dose of your insulin/oral diabetes medicines may need to be adjusted.
Side effects are usually mild and temporary. Side effects may include headaches, muscle pain, joint stiffness, weakness, high blood sugar (hyperglycemia), sugar in your urine (glucosuria), swollen hands and feet due to fluid retention, and redness and itching in the area you inject.
If you have any of these symptoms, discuss them with your doctor.
If you have headaches, eyesight problems, nausea and/or vomiting, these may be symptoms of raised pressure in the brain. Contact your doctor right away.
In very rare cases children treated with somatropin have experienced pain in the hip or knee or a limp. These symptoms may be caused by a slippage of the growth plate in the hip (slipped capital femoral epiphysis).
Scoliosis (curvature of the spine) can occur in children who experience rapid growth. Because growth hormone increases growth rate, children should be monitored for progression of scoliosis.
Thyroid function tests should be performed periodically.
Skin lesions should be checked carefully for any unusual changes.
Somatropin treatment can increase the chances of developing middle ear infections in patients with Turner syndrome.
Congenital heart disease is a common finding in Noonan syndrome and patients should be closely monitored.
Talk to your doctor if you think you have any of these conditions.
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy, and hormone therapy.
Stock info (NYSE quotes delayed by 15 minutes. Currency in USD)